Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats

Neuropharmacology

Volumn 59, Issue 6, 2010, Pages 551-557

  Rezende, Rafael Machado ^a   Paiva Lima, Patrícia ^a   Dos Reis, Webster Glayser Pimenta ^a   Mesquita Camêlo, Vinícius ^a   Bakhle, Y S ^b   Francischi, Janetti Nogueira de ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Celecoxib; Endogenous; Hypoalgesia; Opioids; Tolerance

Indexed keywords

CELECOXIB; INDOMETACIN; MORPHINE; NALTREXONE; PROSTAGLANDIN E2;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; INFLAMMATION; MALE; MORNING DOSAGE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; DINOPROSTONE; HYPERALGESIA; INDOMETHACIN; INFLAMMATION; MORPHINE; PAIN THRESHOLD; PHYSICAL STIMULATION; PYRAZOLES; RATS; SULFONAMIDES;

EID: 77956913107     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.07.022     Document Type: Article

References (60)

1. Alves D., Duarte I.D.G. Involvement of ATP-sensitive potassium channels in the peripheral antinociceptive effect induced by dipyrone. Eur. J. Pharmacol. 2002, 444:47-52.
2. Battistella M., Mamdami M.M., Juurlink D.N., Rabeneck L., Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch. Intern. Med. 2005, 165:189-192.
3. Bingham S., Beswick P.J., Bountra C., Brown T., Campbell I.B., Chessell I.P., Clayton N., Collins S.D., Davey P.T., Goodland H., Gray N., Haslam C., Hatcher J.P., Hunter A.J., Lucas F., Murkitt G., Naylor A., Pickup E., Sargent B., Summerfield S.G., Stevens A., Stratton S.C., Wiseman J. The cyclooxygenase-2 inhibitor GW406381 X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J. Pharmacol. Exp. Ther. 2005, 312:1161-1169.
4. Bohn L.M., Gainetdinov R.R., Lin F.T., Lefkowitz R.J., Caron M.G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408:720-723.
5. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498.
6. +-ATP openers and opioids. Eur. J. Pharmacol. 2001, 417:91-98.
7. Chen Y., Sommer C. The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence. Mol. Neurobiol. 2009, 40:101-107.
8. Cheng P.Y., Svingos A.L., Wang H., Clarke C.L., Jenab S., Beczkowska I.W., Inturrisi C.E., Pickel V.M. Ultrastructural immunolabeling shows prominent presynaptic vesicular localization of delta-opioid receptor within both enkephalin-and nonenkephalin-containing axon terminals in the superficial layers of the rat cervical spinal cord. J. Neurosci. 1995, 15:5976-5988.
9. Chung L., Chakravarty E.F., Kearns P., Wang C., Bush T.M. Bleeding complications in patients on celecoxib and warfarin. J. Clin. Pharm. Ther. 2005, 30:471-477.
10. Correa J.D., Paiva-Lima P., Rezende R.M., Dos Reis W.G.P., Ferreira-Alves D.L., Bakhle Y.S., Francischi J.N. Peripheral μ-, κ- and δ-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. Life Sci. 2010, 86:951-956.
11. Déciga-Campos M., López-Muñoz F.J. Participation of the l-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib. Eur. J. Pharmacol. 2004, 484:193-199.
12. Di Rosa M. Biological properties of carrageenan. J. Pharm. Pharmacol. 1972, 24:89-102.
13. Domer F. Characterization of the analgesic activity of ketorolac in mice. Eur. J. Pharmacol. 1990, 177:127-135.
14. Drew G.M., Lau B.K., Vaughan C.W. Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J. Neurosci. 2009, 29:7220-7229.
15. Dunbar S., Yaksh T.L. Effect of spinal infusion of L-NAME, a nitric oxide synthase inhibitor, on spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Neurosci. Lett. 1996, 207:33-36.
16. Faura C.C., Olaso M.J., Garcia Cabanes C., Horga J.F. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?. Pain 1996, 65:25-30.
17. Ferreira S.H., Lorenzetti B.B., Devissaguet M., Lesieur D., Tsouderos Y. S14080, a peripheral analgesic acting by release of an endogenous circulating opioid-like substance. Br. J. Pharmacol. 1995, 114:303-308.
18. França D.S., Ferreira-Alves D.L., Duarte I.D., Ribeiro M.C., Rezende R.M., Bakhle Y.S., Francischi J.N. Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan. Neuropharmacology 2006, 51:37-43.
19. Frances B., Gout R., Monsarrat B., Cros J., Zajac J.M. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther. 1992, 262:25-31.
20. Francischi J.N., Chaves C.T., Moura A.C.L., Lima A.S., Rocha O.A., Ferreira-Alves D.L., Bakhle Y.S. Selective inhibitors of cycloo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br. J. Pharmacol. 2002, 137:837-844.
21. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., O'Dowd B.F. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 2000, 275:26128-26135.
22. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., Devi L.A. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J. Neurosci. 2000, 20:RC110.
23. Gregori-Puigjané E., Mestres J. A ligand-based approach mining chemogenomic space of drugs. Comb. Chem. High Throughput Screen 2008, 11:669-676.
24. Guan J.S., Xu Z.Z., Gao H., He S.Q., Ma G.Q., Sun T., Wang L.H., Zhang Z.N., Lena I., Kitchen I., Elde R., Zimmer A., He C., Pei G., Bao L., Zhang X. Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia. Cell 2005, 122:619-631.
25. Hawkey C.J. COX-2 inhibitors. Lancet 1999, 353:307-314.
26. Herrero J.F., Headley P.M. Reversal by naloxone of the spinal antinociceptive actions of a systemically administered NSAID. Br. J. Pharmacol. 1996, 118:968-972.
27. Huang Y.M., Wang C.M., Wang C.T., Lin W.P., Horng L.C., Jiang C.C. Perioperative celebrex administration for pain management after total knee arthroplasty a randomized, controlled study. BMC Musculoskelet. Disord. 2008, 9:77.
28. Johnson E.A., Oldfield S., Braksator E., Gonzalez-Cuello A., Couch D., Hall K.J., Mundell S.J., Bailey C.P., Kelly E., Henderson G. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol. Pharmacol. 2006, 70:676-685.
29. Karim A., Tolbert D., Piergies A., Hubbard R.C., Harper K., Wallemark C.B., Slater M., Geis G.S. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J. Clin. Pharmacol. 2000, 40:655-663.
30. Mao J., Price D.D., Mayer D.J. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 1994, 14:2301-2312.
31. Michel R.E., Holt J.C., Domer F.R. Ketorolac causes the release of methionine-enkephalin in rats. Res. Commun. Mol. Pathol. Pharmacol. 1996, 91:249-252.
32. Ocaña M., Cendán C.M., Cobos E.J., Entrena J.M., Baeyens J.M. Potassium channels and pain: present realities and future opportunities. Eur. J. Pharmacol. 2004, 500:203-219.
33. Ossipov M.H., Lai J., King T., Vanderah T.W., Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 2005, 80:319-324.
34. Paulson S.K., Zhang J.Y., Breau A.P., Hribar J.D., Liu N.W., Jessen S.M., Lawal Y.M., Cogburn J.N., Gresk C.J., Markos C.S., Maziasz T.J., Schoenhard G.L., Burton E.G. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug. Metab. Dispos. 2000, 28:514-521.
35. Pernia-Andrade A.J., Tortorici V., Vanegas H. Induction of opioid tolerance by lysine-acetylsalicylate in rats. Pain 2004, 111:191-200.
36. Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell. Biochem. 2007, 42:3-27.
37. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther 1957, 111:409-419.
38. Reis G.M., Duarte I.D. Baclofen, an agonist at peripheral GABA B receptors, induces antinociception via activation of TEA-sensitive potassium channels. Br. J. Pharmacol. 2006, 149:733-739.
39. Reuben S.S., Buvenandran A., Katz B., Kroin J.S. A prospective randomized trial on the role of perioperative celecoxib administration for total knee arthroplasty: improving clinical outcomes. Anesth. Analg. 2008, 106:1258-1264.
40. Rezende R.M., Dos Reis W.G., Duarte I.D., Lima P.P., Bakhle Y.S., Francischi J.N. The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. Pain 2009, 142:94-100.
41. Rezende R.M., França D.S., Menezes G.B., Dos Reis W.G.P., Bakhle Y.S., Francischi J.N. Different mechanisms underlie the analgesic actions of paracetamol and dipyrone in a rat model of inflammatory pain. Br. J. Pharmacol. 2008, 153:760-768.
42. Rozenfeld R., Abul-Husn N.S., Gomez I., Devi L.A. An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. ScientificWorldJournal 2007, 7:64-73.
43. Shi S., Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol. 2008, 64:233-252.
44. Terman G.W., Shavit Y., Lewis J.W., Cannon J.T., Liebeskind J.C. Intrinsic mechanisms of pain inhibition: activation by stress. Science 1984, 226:1270-1277.
45. Tortorici V., Aponte Y., Acevedo H., Nogueira L., Vanegas H. Tolerance to non-opioid analgesics in PAG involves unresponsiveness of medullary pain-modulating neurons in male rats. Eur. J. Neurosci. 2009, 29:1188-1196.
46. Tortorici V., Morgan M.M., Vanegas H. Tolerance to repeated microinjection of morphine into the periaqueductal gray is associated with changes in the behavior of off- and on-cells in the rostral ventromedial medulla. Pain 2001, 89:237-244.
47. Tortorici V., Vanegas H. Opioid tolerance induced by metamizol (dipyrone) microinjections into the periaqueductal gray of rats. Eur. J. Neurosci. 2000, 12:4074-4080.
48. Traynor J.R., Elliott J. Delta-opioid receptor subtypes and cross-talk with mu-receptors. Trends Pharmacol. Sci. 1993, 14:84-86.
49. Troullos E., Hargreaves K.M., Dionne R.A. Ibuprofen elevates immunoreative beta-endorphin levels in humans during surgical stress. Clin. Pharmacol. Ther. 1997, 62:74-81.
50. Vanegas H., Tortorici V. Opioidergic effects of nonopioid analgesics on the central nervous system. Cell. Mol. Neurobiol. 2002, 22:655-661.
51. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231:232-235.
52. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998, 38:97-120.
53. Vaughan C.W. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurons. Br. J. Pharmacol. 1998, 123:1479-1481.
54. Vaughan C.W., McGregor I.S., Christie M.J. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br. J. Pharmacol. 1999, 127:935-940.
55. Vinegar R., Truax J.F., Selph J.L., Johnston P.R., Venable A.L., McKenzie K.K. Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed. Proc. 1987, 46:118-146.
56. Werner U., Werner D., Rau T., Fromm M.F., Hinz B., Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin. Pharmacol. Ther. 2003, 74:130-137.
57. Wittwer E., Kern S.E. Role of morphine's metabolites in analgesia: concepts and controversies. AAPS J. 2006, 8:E348-E352.
58. Zhang J., Ferguson S.S., Barak L.S., Bodduluri S.R., Laporte S.A., Law P.Y., Caron M.G. Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsivesness. Proc. Natl. Acad. Sci. U S A 1998, 95:7157-7162.
59. Zhang X., Bao L., Arvidsson U., Elde R., Hökfelt T. Localization and regulation of the delta-opioid receptor in dorsal root ganglia and spinal cord of the rat and monkey: evidence for association with the membrane of large dense-core vesicles. Neuroscience 1998, 82:1225-1242.
60. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.